Claims
- 1-47. (canceled)
- 48. A method of treating respiratory disease in a mammal comprising administering to a mammal in need of such treatment
(a) a compound of formula (I) 145 a stereoisomer or solvate thereof, or a pharmaceutically acceptable salt of said compound, stereoisomer, or solvate, wherein: R1 and R2 are each independently hydrogen or methyl; X and Y together are CH2—CH(OH)—Ar or CH2—C(O)—Ar, or X is a covalent bond, NR3 or CHR4, wherein, R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6, and R4 is hydrogen or methyl, and Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6; Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6; n is independently for each occurrence 0, 1 or 2; R5 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl; and R6 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl; or, (b) a pharmaceutical composition comprising said compound of formula (I), said stereoisomer or solvate thereof, or said pharmaceutically acceptable salt of said compound, stereoisomer, or solvate; and a pharmaceutically acceptable carrier, vehicle, or diluent.
- 49. The method of claim 48 wherein the disease is adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, bronchiectasis, chronic sinusitis or rhinitis.
- 50. A method of treating inflammation in a mammal comprising administering to a mammal in need of such treatment:
(a) a compound of formula (I) 146 a stereoisomer or solvate thereof, or a pharmaceutically acceptable salt of said compound, stereoisomer, or solvate, wherein: R1 and R2 are each independently hydrogen or methyl; X and Y together are CH2—CH(OH)—Ar or CH2—C(O)—Ar, or X is a covalent bond, NR3 or CHR4, wherein, R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6, and R4 is hydrogen or methyl, and Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6; Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6; n is independently for each occurrence 0, 1 or 2; R5 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl; and R6 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl or, (b) a pharmaceutical composition comprising said compound of formula (I), said stereoisomer or solvate thereof, or said pharmaceutically acceptable salt of said compound, stereoisomer, or solvate; and a pharmaceutically acceptable carrier, vehicle, or diluent.
- 51. A method of stimulating an A2a receptor in a mammal comprising administering to a mammal in need of such stimulation:
(a) a compound of formula (I) 147 a stereoisomer or solvate thereof, or a pharmaceutically acceptable salt of said compound, stereoisomer, or solvate, wherein: R1 and R2 are each independently hydrogen or methyl; X and Y together are CH2—CH(OH)—Ar or CH2—C(O)—Ar, or X is a covalent bond, NR3 or CHR4, wherein, R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6, and R4 is hydrogen or methyl, and Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6; Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6; n is independently for each occurrence 0, 1 or 2; R5 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl; and R6 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl or, (b) a pharmaceutical composition comprising said compound of formula (I), said stereoisomer or solvate thereof, or said pharmaceutically acceptable salt of said compound, stereoisomer, or solvate; and a pharmaceutically acceptable carrier, vehicle, or diluent.
- 52. A method of treating septic shock, male erectile dysfunction, hypertension, stroke, epilepsy, cerebral ischaemia, peripheral vascular disease, post-ischaemic reperfusion injury, diabetes, rheumatoid arthritis, multiple sclerosis, psoriasis, allergic dermatitis, eczema, ulcerative colitis, Crohns disease, inflammatory bowel disease, Heliobacter pylori-gastritis, non-Heliobacter pylori gastritis, non-steroidal anti-inflammatory drug-induced damage to the gastro-intestinal tract or a psychotic disorder, or promoting wound healing in a mammal comprising administering to a mammal in need of such treatment:
(a) a compound of formula (I) 148 or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 and R2 are each independently hydrogen or methyl; X and Y together are CH2—CH(OH)—Ar or CH2—C(O)—Ar, or X is a covalent bond, NR3 or CHR4, wherein, R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6, and R4 is hydrogen or methyl, and Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6; Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR5R6; n is independently for each occurrence 0, 1 or 2; R5 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl; and R6 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl or, (b) a pharmaceutical composition comprising said compound of formula (I), said stereoisomer or solvate thereof, or said pharmaceutically acceptable salt of said compound, stereoisomer, or solvate; and a pharmaceutically acceptable carrier, vehicle, or diluent.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0015727.1 |
Jun 2000 |
GB |
|
Parent Case Info
[0001] This application is a continuation of copending prior filed foreign application Great Britain Serial No. 0015727.1, filed Jun. 27, 2000 (Attorney Docket No. PC10920), the benefit of the filing date of which is claimed, and which is incorporated herein by reference in its entirety; and is a continuation of prior filed provisional application U.S. Ser. No. 60/218,466, filed Jul. 14, 2000 (Attorney Docket No. PC10920), the benefit of the filing date of which is claimed, and which is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60218466 |
Jul 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09884244 |
Jun 2001 |
US |
Child |
10869380 |
Jun 2004 |
US |